Search details
1.
Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE.
Br J Cancer
; 130(8): 1348-1355, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38347093
2.
Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
Cancer Sci
; 114(1): 221-226, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36168844
3.
Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103).
Cancer
; 128(11): 2174-2181, 2022 06 01.
Article
in English
| MEDLINE | ID: mdl-35285940
4.
Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy.
Cancer
; 128(3): 536-546, 2022 Feb 01.
Article
in English
| MEDLINE | ID: mdl-34614209
5.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
N Engl J Med
; 380(25): 2395-2405, 2019 06 20.
Article
in English
| MEDLINE | ID: mdl-31157962
6.
Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
Breast Cancer Res Treat
; 194(1): 171-178, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35538268
7.
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Breast Cancer Res
; 23(1): 87, 2021 08 23.
Article
in English
| MEDLINE | ID: mdl-34425869
8.
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Cancer Sci
; 112(6): 2381-2392, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33686753
9.
Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial.
Cancer
; 127(14): 2545-2552, 2021 07 15.
Article
in English
| MEDLINE | ID: mdl-33793979
10.
Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.
Br J Cancer
; 124(3): 604-615, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33139797
11.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
N Engl J Med
; 379(2): 111-121, 2018 Jul 12.
Article
in English
| MEDLINE | ID: mdl-29860917
12.
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Breast Cancer Res Treat
; 186(2): 417-428, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33392835
13.
Gold Nanobipyramids as Second Near Infrared Optical Coherence Tomography Contrast Agents for in Vivo Multiplexing Studies.
Nano Lett
; 20(1): 101-108, 2020 01 08.
Article
in English
| MEDLINE | ID: mdl-31585502
14.
Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology.
Cancer
; 126(8): 1605-1613, 2020 04 15.
Article
in English
| MEDLINE | ID: mdl-31967687
15.
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Oncologist
; 25(2): e243-e251, 2020 02.
Article
in English
| MEDLINE | ID: mdl-32043763
16.
Real-Time Detection of Circulating Tumor Cells in Living Animals Using Functionalized Large Gold Nanorods.
Nano Lett
; 19(4): 2334-2342, 2019 04 10.
Article
in English
| MEDLINE | ID: mdl-30895796
17.
Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
Breast Cancer Res
; 21(1): 98, 2019 08 28.
Article
in English
| MEDLINE | ID: mdl-31462307
18.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
N Engl J Med
; 373(21): 2005-14, 2015 Nov 19.
Article
in English
| MEDLINE | ID: mdl-26412349
19.
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).
Breast Cancer Res Treat
; 169(3): 537-548, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29455298
20.
Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers.
Mol Carcinog
; 57(4): 567-575, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29240257